Skip to main content
. 2010 Sep;35(9 Section 2):2–4.

TABLE 4.

Adverse reactions occurring in patients >2% (Study 3 and Study 4)

Preferred term (sorted by SOC) VIMOVO 500 mg/20 mg twice daily (n=246) % Placebo (n=490) %
Gastrointestinal disorders
Dyspepsia 8 12
Diarrhea 6 4
Abdominal pain upper 4 3
Constipation 4 1
Nausea 4 4
Nervous system disorders
Dizziness 3 2
Headache 3 5
General disorders and administration site conditions
Peripheral edema 3 1
Respiratory, thoracic and mediastinal disorders
Cough 1 3
Infections and infestations
Sinusitis 1 2